<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885806</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 15388913.6.0000.5149</org_study_id>
    <nct_id>NCT01885806</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to evaluate the safety and efficacy of repetitive transcranial magnetic stimulation
      (rTMS) for apathy treatment in patients with Alzheimer's disease (AD). We hypothesize that
      rTMS will be superior to placebo to reduce apathy symptoms and severity in patients with AD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to enroll 40 patients with mild and moderate Alzheimer's disease with apathy
      symptoms that will be randomized to receive rTMS or sham procedure. Subjects will be
      randomized in two arms (rTMS or sham procedure) in 1:1 proportion.

      Eligibility criteria:

        -  Diagnosis of Alzheimer's disease, mild and moderate stage (MMSE range from 10 to 20);

        -  Diagnosis of apathy;

        -  age between 60 and 85 years-old;

        -  On stable doses of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or
           memantine for at least 6 months prior to enrollment;

      The primary outcome measures is the Apathy Inventoire. Secondary outcome measures are the NPI
      score, ADAS-cog scores and the Zarit Burden Scale scores.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in apathy symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction of 30% in the Apathy Inventoire scores between baseline and 12 weeks after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ADAS-Cog scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in ADAS-Cog scores between baseline and 12 weeks after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Zarit Burden Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reduction in the Zarit Burden Scale between baseline and 12 weeks after treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessment</measure>
    <time_frame>4th week, 8th week, 12th week</time_frame>
    <description>Assessment of rTMS safety by the UKU scale.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Apathy</condition>
  <arm_group>
    <arm_group_label>Repetitive TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:
Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Stimulator Magstim Rapid 2</intervention_name>
    <description>All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freq√ºency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex</description>
    <arm_group_label>Repetitive TMS</arm_group_label>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Magnetic Stimulator</intervention_name>
    <description>This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.
Total of session: 10</description>
    <arm_group_label>Sham TMS</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 60 to 85 years-old

          -  Mild or moderate Alzheimer's disease (MMSE scores between 10 and 20)

          -  Apathy diagnosis

          -  On stable doses of cholinesterase inhibitors (donepezil, galantamine, rivastigmine)
             and/or memantine for at least 6 months prior to enrollment

        Exclusion Criteria:

          -  history of epilepsy or convulsions

          -  History of migraine or headaches episodes twice per week or more

          -  History of neurodegenerative diseases other than Alzheimer's disease

          -  Current use of first generation antipsychotics, clozapine, tricyclic drugs or
             anticonvulsants

          -  History of cerebral ischemic episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Breno S Diniz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Breno S Diniz, MD, PhD</last_name>
    <phone>+55 31 97950860</phone>
    <email>brenosatler@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal University of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Outside of U.S.</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco A Romano-Silva, MD, PhD</last_name>
      <phone>+55 31 3409-9758</phone>
      <email>romanosilva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Breno S Diniz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal University of Minas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Outside of U.S.</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco A Romano-Silva, MD, PhD</last_name>
      <phone>+55 31 3409-9785</phone>
      <email>romanosilva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Breno S Diniz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Breno Satler de Oliveira Diniz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Apathy; Alzheimer's disease; Cognition; Burden of Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

